<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469181</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0679</org_study_id>
    <nct_id>NCT02469181</nct_id>
  </id_info>
  <brief_title>Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)</brief_title>
  <official_title>Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy : A Prospective Multi-modality Imaging Study Using Diastolic Stress Echocardiography, LV Vortex Flow and Cardiac MRI(RECAFTURE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of ERT on LV diastolic function and flow&#xD;
      in patients with Fabry's cardiomyopathy using diastolic stress echocardiography, LV vortex&#xD;
      flow and CMR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Objectives -The purpose of this study is to evaluate the impact of ERT on LV diastolic&#xD;
           function and flow in patients with Fabry's cardiomyopathy using diastolic stress&#xD;
           echocardiography, LV vortex flow and CMR.&#xD;
&#xD;
        2. Primary / Secondary Endpoint 1) Primary endpoint&#xD;
&#xD;
             -  Changes of peak exercise E/E' by diastolic stress echocardiography (RECAP-F STRESS&#xD;
                trial) and LV vortex flow parameters (RECAP-F FLOW trial) at 1 year follow up.&#xD;
&#xD;
                2) Secondary endpoint&#xD;
&#xD;
             -  Changes of extracellular volume by CMR(T1 mapping) at 1 year follow up (RECAP-F&#xD;
                trial) ② Evaluation of the degree of the resting LV diastolic function ③ Other&#xD;
                echo-parameters; LV mass index at baseline, 1 year follow up, reduction of peak&#xD;
                exercise E/E prime at 1 year follow up&#xD;
&#xD;
                  -  Changes of quality of life using questionnaire ⑤ Change of peak VO2, exercise&#xD;
                     time, AT by diastolic stress echocardiography at 1 year follow up ⑥ Change in&#xD;
                     T1 baseline(myo, ms) &amp; T1 baseline(blood, ms) T1 postcontrast(myo, ms) &amp; T1&#xD;
                     baseline(blood, ms) by CMR&#xD;
&#xD;
        3. Study Methods 1) Study Design : 28 patients with newly diagnosed genetically confirmed&#xD;
           Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow&#xD;
           analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and&#xD;
           after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).&#xD;
&#xD;
      2) Study procedures : Examinations as described below will be done before ERT and 1 year&#xD;
      later&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2015</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of peak exercise E(velocity of early)/E'(Early diastolic) by diastolic stress echocardiography</measure>
    <time_frame>1 year after the echocardiography</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of peak VO2 by diastolic stress echocardiography</measure>
    <time_frame>1 year after the echocardiography</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of peak exercise time by diastolic stress echocardiography</measure>
    <time_frame>1 year after the echocardiography</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV(left ventricular) vortex flow analysis by contract echocardiography</measure>
    <time_frame>1 year after the echocardiography</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of extracellular volume by Cardiac MRI(CMR)</measure>
    <time_frame>1 year after the CMR</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Fabry's Disease</condition>
  <arm_group>
    <arm_group_label>FD(Fabry disease) group</arm_group_label>
    <description>28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lyso GL-3&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 16~75years with Fabry's disease who were confirmed by enzyme assay and gene&#xD;
        study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 16~75 years with Fabry's disease who were confirmed by enzyme assay and&#xD;
             gene study&#xD;
&#xD;
          -  All patients should have LV hypertrophy in 2D echocardiography (end diastolic septum&#xD;
             and posterior wall thickness ≥12mm)&#xD;
&#xD;
          -  Patients provided with the written, informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for agalsidase beta enzyme replacement treatment&#xD;
&#xD;
          -  Patients who cannot perform supine bicycle stress echocardiography, contrast&#xD;
             echocardiography or cardiac MRI&#xD;
&#xD;
          -  Hemodynamically significant valvular heart disease or arrythmias&#xD;
&#xD;
          -  History of acute myocardial infarction or congestive heart failure with reduced LV&#xD;
             ejection fraction of less than 35%&#xD;
&#xD;
          -  CVA in the prior 6 months&#xD;
&#xD;
          -  Scheduled or planned surgery in the next 6 months&#xD;
&#xD;
          -  Chronic liver cirrhosis&#xD;
&#xD;
          -  Allergy to contrast agent (Definity®, Lantheus Medical Imaging, North Billerica, MA,&#xD;
             USA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Geu Ru Hong, M.D., Ph.D.</last_name>
    <phone>82-2-2228-8443</phone>
    <email>grhong@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geu-Ru Hong, MD, PhD</last_name>
      <phone>82-2-2228-8443</phone>
      <email>GRHONG@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

